India Specialty Volume Growth
>35%
+35pp YoY
Specialty segment in India grew over 35% year-on-year, offsetting weakness in performance actives.
GALAXYSURFACTANTS
Other
10 Feb 2026
Galaxy Surfactants Limited — Q3 FY26
Galaxy Surfactants reported Q3 FY26 EBITDA of ₹124 crore, up 13% YoY, driven by strong specialty volume growth in India (+35%) and rest-of-world markets, partially offset by continued reformulation pressures from a key Indian tier-1 account and US tariff he...
✓ Verified against BSE filing
2-Min Summary
Galaxy Surfactants reported Q3 FY26 EBITDA of ₹124 crore, up 13% YoY, driven by strong specialty volume growth in India (+35%) and rest-of-world markets, partially offset by continued reformulation pressures from a key Indian tier-1 account and US tariff headwinds. EBITDA per metric ton improved to ₹20,156 from ₹17,527 last year, aided by cost efficiencies and a favorable mix shift toward high-margin prestige specialties. India performance actives declined ~4% due to reformulation, while the specialty segment grew >35%. The US reciprocal tariff reduction from 50% to 18% is a major structural positive, expected to revive pipeline projects from late Q4. However, fatty alcohol prices remain elevated, and the Egypt/AMET region saw high-teens volume decline due to competitive intensity. Management expects gradual recovery in India with new formulations commercializing in Q4, but near-term visibility remains limited. Key risk: sustained high fatty alcohol prices could prolong reformulation and delay volume recovery.
Key Numbers
AMET Volume Decline
High-teens
-18% YoY
AMET region volumes declined in high teens due to market share losses and competitive intensity.
EBITDA per Metric Ton
₹20,156
+15% YoY
EBITDA per ton improved to ₹20,156 from ₹17,527, driven by mix and cost efficiencies.
US Tariff Reduction
50% to 18%
-32pp
Reciprocal US tariff on Indian exports reduced from 50% to 18%, restoring competitiveness.
Management Guidance
India specialty volume growth to remain double-digit
Management expects double-digit volume growth in the specialty segment in India, supported by new product launches and customer approvals.
growthNew reformulation products to commercialize in Q4 FY26
Alternate formulations for key tier-1 customers are under approval and expected to start commercialization in Q4 FY26.
revenueUS specialty pipeline projects to restart from late Q4
With tariff reduction, customer projects put on hold are expected to resume, contributing from late Q4 FY26 and Q1 FY27.
growthFatty alcohol prices expected to correct from May 2026
Management expects fatty alcohol prices to start correcting from May onwards due to seasonal palm production increases.
otherKey Risks
Sustained high fatty alcohol prices
Fatty alcohol prices remain elevated, prolonging reformulation pressures and delaying volume recovery in India.
high · management_commentaryUS demand slowdown flagged by key customers
Key US customers have flagged demand concerns in beauty and wellbeing, which could temper specialty volume recovery despite tariff relief.
medium · analyst_questionAMET market share loss may be permanent
Management acknowledged that peak volumes in AMET are unlikely to return due to backward-integrated local competitors and currency depreciation in Egypt.
high · analyst_questionEPC project contribution not significant
The EPC project with a US customer provides only modest income and is not expected to materially impact earnings.
low · data_observationNotable Quotes
If the first half was about resilience, our Q3 has been a quarter where multiple headwinds converged testing our agility, execution and resolve.
We are confident that the worst is behind us with the India growth story improving, volume gradually recovering, incremental profitability expected from the recent US India tariff reduction announcement and a sustained improvement in our premium specialty product mix.
I don't see that we'll be able to come back to the peak volumes [in AMET] very clearly.